ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 275 entries already.
Entries by Maren Kühr
New Executive Director of Innovative Health Initiative
The Innovative Health Initiative (IHI) Governing Board has appointed Niklas Blomberg to be the next Executive Director of the organisation. Dr Blomberg has extensive experience of working in Europe’s life science sector, and is currently Director of ELIXIR, the European life sciences data infrastructure. He will take up his duties at IHI in early 2024.
Cresset creates new Vice President role
UK-based CRO Cresset has expanded its senior leadership team with the appointment of Nick Foster as Vice President of their Discovery CRO business.
Closed Loop Medicine appoints new COO
The appointment of Kate Woolland as new Chief Operating Officer of London-based Closed Loop Medicine Ltd supports delivery of the Company’s product and partnership programs.
Biotech companies challenged in times of inflation
Inflation has rebounded with a vengeance from its pandemic-induced recession lows. The US headline inflation rate surged to levels not seen since Ronald Reagan’s presidency, while the Eurozone’s Harmonised Index of Consumer Price (HICP) rose to the highest level in its entire 30-year lifespan.
Amarna Therapeutics appoints new CEO
Leiden-based Amarna Therapeutics announces the appointment of Dr Henk Streefkerk as the company’s new Chief Executive Officer and Medical Director. Streefkerk has already been Amarna’s Medical Director since mid-2022.
Lonza offers PBPK service
Physiologically based pharmacokinetic (PBPK) modelling is a tool that can have a huge impact in speeding up drug development. It simulates a range of physiological factors that have an effect on how an orally dosed drug behaves, flagging up any areas where performance might be expected to be sub-optimal. This allows them to be addressed at an early stage, rather than causing bigger problems later on that might hold up development while a solution is sought.
Premium immune cells for cell & gene therapy research and development
Real Quality. Real Results. With cell & gene therapies, the process is the product – so ensuring high-quality starting material is a critical first step in maximizing your results.
Building on the successes of Europe’s bioeconomy
The bioeconomy can be a major driver in bringing circularity, sustainability and competitive production to Europe as it aims towards becoming climate-neutral and more self-sufficient.
Immunovia AB with new CEO
Jeff Borcherding, President of Immunovia’s US subsidiary since April 2022, has been the new Global CEO of Sweden’s Immunovia AB since the end of April.